Previously recorded as Evaxion Biotech APS (to 2021)
Recorded as renamed to Evaxion A/S (2026)
15 patents currently held
2 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in Apr 2032. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
Apr 2032
Next term end
8
Patent families
When these terms end
Held patents by the year their term ends
notable patents
all others
Updated Nov 20, 2026 · includes USPTO assignment data published Nov 19, 2026, status data published Nov 20, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Apr 2032 · High confidence
Also notable
Ends Jan 2036 · High confidence
Also notable
Ends Jan 2038 · High confidence
Also notable
Ends May 2035 · High confidence
Also notable
Ends Nov 2037 · High confidence
Also notable
Ends Feb 2037 · High confidence
Also notable
Ends Jul 2036 · High confidence
Proteins and Nucleic Acids Useful in Vaccines Targeting Staphylococcus Aureus
US 9,085,631
The largest patent family in this portfolio, 7 related applications, renewed at every maintenance window due so far. Protection runs to 2032.
Proteins and nucleic acids useful in vaccines targeting Klebsiella Pneumoniae
US 10,434,162
A family of 5 related applications built on the 2019 grant. Protection runs to 2036.
Vaccines targeting Pseudomonas aeruginosa
US 11,718,648
Granted 2023. Computed term ends 2038.
Proteins and nucleic acids useful in vaccines targeting Staphylococcus aureus
US 11,807,669
Granted 2023. Computed term ends 2035.
Chimeric proteins for inducing immunity towards infection with S. aureus
US 11,414,464
Granted 2022. Computed term ends 2037.
Proteins and nucleic acids useful in vaccines targeting Staphylococcus aureus
US 10,946,084
Granted 2021. Computed term ends 2037.
Proteins and nucleic acids useful in vaccines targeting pseudomonas aeruginosa
US 12,006,342
Granted 2024. Too new for citation comparison; protection runs to 2036.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Jan 21, 2027The maintenance fee for Proteins and Nucleic Acids Useful in Vaccines Targeting Staphylococcus Aureus (US 9,085,631) comes due Jan 21, 2027. Unpaid by Jul 21, 2027, it lapses early.
- 1 fee due Feb 8, 2027The maintenance fee for Vaccines targeting Pseudomonas aeruginosa (US 11,718,648) comes due Feb 8, 2027. Unpaid by Aug 9, 2027, it lapses early.
- 1 fee due Apr 8, 2027The maintenance fee for Proteins and nucleic acids useful in vaccines targeting Klebsiella Pneumoniae (US 10,434,162) comes due Apr 8, 2027. Unpaid by Oct 8, 2027, it lapses early.
- 1 fee due May 7, 2027The maintenance fee for Proteins and nucleic acids useful in vaccines targeting Staphylococcus aureus (US 11,807,669) comes due May 7, 2027. Unpaid by Nov 8, 2027, it lapses early.
- 1 fee due Jul 2, 2027The maintenance fee for Peptides derived from Acinetobacter Baumannii and their use in vaccination (US 11,857,615) comes due Jul 2, 2027. Unpaid by Jan 3, 2028, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
What they patent
The largest of its 8 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
| Proteins and Nucleic Acids Useful in Vaccines Targeting Staphylococcus Aureus | 5 in force | to Apr 2032 |
| Proteins and nucleic acids useful in vaccines targeting Klebsiella Pneumoniae | 3 in force | to Jan 2036 |
| Chimeric proteins for inducing immunity towards infection with S. aureus | 2 in force | to Nov 2037 |
| Vaccines targeting Pseudomonas aeruginosa | 1 in force | to Jan 2038 |
| Proteins and nucleic acids useful in vaccines targeting Staphylococcus aureus (2018) | 1 in force | to Feb 2037 |
| Proteins and nucleic acids useful in vaccines targeting pseudomonas aeruginosa | 1 in force | to Jul 2036 |
| Peptides derived from Acinetobacter Baumannii and their use in vaccination | 1 in force | to Jan 2036 |
| Proteins and nucleic acids useful in vaccines targeting Staphylococcus aureus (2019) | 1 in force | to May 2035 |
Patents held now
Soonest term end first.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,085,631 | Proteins and Nucleic Acids Useful in Vaccines Targeting Staphylococcus Aureus In force · High confidence | In force | High confidence | |
| US 9,534,022 | Proteins and Nucleic Acids Useful in Vaccines Targeting Staphylococcus Aureus In force · High confidence | In force | High confidence | |
| US 10,034,928 | Proteins and Nucleic Acids Useful in Vaccines Targeting Staphylococcus Aureus In force · High confidence | In force | High confidence | |
| US 10,675,340 | Proteins and nucleic acids useful in vaccines targeting Staphylococcus aureus In force · High confidence | In force | High confidence | |
| US 11,052,145 | Proteins and nucleic acids useful in vaccines targeting Staphylococcus aureus In force · High confidence | In force | High confidence | |
| US 11,807,669 | Proteins and nucleic acids useful in vaccines targeting Staphylococcus aureus In force · High confidence | In force | High confidence | |
| US 11,857,615 | Peptides derived from Acinetobacter Baumannii and their use in vaccination In force · Medium confidence | In force | Medium confidence | |
| US 10,434,162 | Proteins and nucleic acids useful in vaccines targeting Klebsiella Pneumoniae In force · High confidence | In force | High confidence | |
| US 10,849,968 | Proteins and nucleic acids useful in vaccines targeting Klebsiella pneumoniae In force · High confidence | In force | High confidence | |
| US 12,226,469 | Proteins and nucleic acids useful in vaccines targeting Klebsiella pneumoniae In force · High confidence | In force | High confidence |
Also on record, not counted in the 15: 2 patents in force now held by others · 16 applications pending · 6 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.